ACAD
$20.74+0.02 (+0.10%)
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for ...
Recent News
ACADIA Pharmaceuticals Maps Key CNS Readouts: Remlifanserin ADP Data Due Aug–Oct, ACP-211 Next Year
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives discussed upcoming clinical readouts and pipeline priorities during the company’s virtual CNS conference, with a focus on remlifanserin (formerly ACP-204) in Alzheimer’s disease psychosis (ADP), an ongoing Phase 2 program in Lewy body dementia psychosi
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness
Recent share performance and business snapshot ACADIA Pharmaceuticals (ACAD) has attracted attention after a weak spell in the stock, with shares showing declines over the past week, month and past 3 months, despite a higher total return over the past year. For context, the company reports annual revenue of US$1,071.505m and net income of US$391.0m, supported by products focused on neurological and rare diseases, including treatments for Parkinson’s disease psychosis and Rett syndrome. See...
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?
Axsome's lead product, Auvelity, sales jumped 74% to $507M in 2025, fueling growth while other drugs added momentum.
ACADIA Pharmaceuticals Showcases $1B+ Net Sales, $800M Cash, and Key Alzheimer’s Readout Ahead
ACADIA Pharmaceuticals (NASDAQ:ACAD) highlighted its growing commercial portfolio, upcoming clinical catalysts, and cash position during a presentation at the Citizens Life Sciences Conference, with remarks from CFO Mark Schneyer and Head of Clinical Development Srdjan Stankovic. Commercial portfol
JAZZ or ACAD: Which Is the Better Value Stock Right Now?
JAZZ vs. ACAD: Which Stock Is the Better Value Option?